Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

sanolabor, d.d. - tableta - danazol

Evropska unija - slovenščina - EMA (European Medicines Agency)

bial portela & companhia s.a. - opikapon - parkinsonova bolezen - anti-parkinsonska zdravila - ontilyv is indicated as adjunctive therapy to preparations of levodopa/ dopa decarboxylase inhibitors (ddci) in adult patients with parkinson’s disease and end-of-dose motor fluctuations who cannot be stabilised on those combinations.

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

sandoz d.d. - zolmitriptan - orodisperzibilna tableta - zolmitriptan 2,5 mg / 1 tableta - zolmitriptan

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

sandoz d.d. - zolmitriptan - orodisperzibilna tableta - zolmitriptan 5 mg / 1 tableta - zolmitriptan

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

sandoz d.d. - zolmitriptan - orodisperzibilna tableta - zolmitriptan 2,5 mg / 1 tableta - zolmitriptan

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

sandoz d.d. - zolmitriptan - orodisperzibilna tableta - zolmitriptan 5 mg / 1 tableta - zolmitriptan

Evropska unija - slovenščina - EMA (European Medicines Agency)

instituto grifols s.a. - Človekove normalno imunoglobulina - mucocutaneous lymph node syndrome; guillain-barre syndrome; bone marrow transplantation; purpura, thrombocytopenic, idiopathic; immunologic deficiency syndromes - imunski sera in imunoglobulini, - replacement therapy in adults, children and adolescents (0-18 years) in: , primary immunodeficiency syndromes with impaired antibody production;, hypogammaglobulinaemia and recurrent bacterial infections in patients with chronic lymphocytic luekaemia, in whom prophylactic antibiotics have failed;, hypogammaglobulinaemia and recurrent bacterial infections in plateau-phase-multiple-myeloma patients who failed to respond to pneumococcal immunisation;, hypogammaglobulinaemia in patients after allogenic haematopoietic-stem-cell transplantation (hsct);, congenital aids with recurrent bacterial infections. , immunomodulation in adults, children and adolescents (0-18 years) in: , primary immune thrombocytopenia (itp), in patients at high risk of bleeding or prior to surgery to correct the platelet count;, guillain barré syndrome;, kawasaki disease.

Evropska unija - slovenščina - EMA (European Medicines Agency)

sanofi pasteur - chimeric yellow fever dengue virus serotype 1 (live, attenuated), chimeric yellow fever dengue virus serotype 2 (live, attenuated), chimeric yellow fever dengue virus serotype 3 (live, attenuated), chimeric yellow fever dengue virus serotype 4 (live, attenuated) - dengue - cepiva - dengvaxia is indicated for the prevention of dengue disease caused by dengue virus serotypes 1, 2, 3 and 4 in individuals 6 to 45 years of age with test-confirmed previous dengue infection (see sections 4. 2, 4. 4 in 4. uporaba dengvaxia mora biti v skladu z uradnimi priporočili.